


# Consensus on the stepwise approach enhanced surveillance implementation:



Summary of the discussions and conclusions


Proposal and timeline for the next steps

# Q1: The operational aspects of the national AMR surveillance system in your country is coordinated by (choose one)




- Majority of countries have an NCC and/or NRL (61%)
- Caribbean countries will receive an official request to participate in the early implementation of the protocol: Further advocate importance
- Comments: Curacao, Haiti

## Q2: Which expertise is represented in the national AMR coordinating team (select all applicable)




- Multidisciplinary teams with highest representation of medical microbiologists
- Importance of inclusion of disciplines:
  - Datamanager/epidemiologist
  - Clinician/ID specialistTo ensure translation of data to action!
- How can PAHO support with strengthening multi-disciplinary teams?
- Comments: Argentina, Suriname

### Q3: Which data fields are uniformly available at the local surveillance sites (multiple options)




- Majority of data are available!
- Date of admission and HAI/CAI is most challenging
- Data of admission is often available at the local surveillance sites. Working towards including this information into the data collection process.

# Q4: Which of the following definitions for HAI and CAI is used at the national level in your country ? (choose one)




- When countries are able to provide the admission and specimen date the global international standard identification will be used to as the **gold standard**
- Comments: Uruguay, Belize, Peru

## Q5: Which of the analysis properties of the new protocol do you consider most important/useful (multiple options)




- Priority is given to the automated feedback, dashboards and PLISA portal for data upload
- Important message! Move ahead with the implementation of the analysis properties at PAHO level

# Q6: Should regional data analyses be based on the final SIR interpretation reported by the country?



- SIR interpretation the basis of the resistance proportions calculated,
  - Ensure inclusion of SIR adaptations in case of additional testing
  - Ensure the %SIR is similar at national, regional and global level
  - Final interpretation is the country responsibility
  - Additional analysis using the 'raw' data to measure impact of changes in breakpoint

# Q7: How should the use of regional database for data analysis and reporting be organized? (Multiple selections are possible)




- Richness of the data requires reiteration of agreement:
  - PAHO will only use data as per the protocol objectives
  - Country approval for additional data use, including use of anonymized hospital/lab level data
- Publications on behalf of the network:
  - Network as author
  - Naming institutes in footnote or acknowledgements

Suggest to include these agreements in the protocol or publish on the PAHO-AMR website



# Q8: Which of the values do you expect to be able to retrieve/collect from the local surveillance sites (multiple selections are possible)



- Total # blood culture sets, Hospital size and Patient admissions mostly available
- More challenging are patient days, level of hospital care, occupancy rate

Identify frontrunners that are able to provide this kind of information (through PLISA)

# Q9: At the national level, do you intend to make use of the standard WHONET configuration that will be provided?

- Standard WHONET configuration and WHONET manual will be provided next week! ENG/ESP

Origen: Humano

Origen de identificación: [ ] Fecha de nacimiento: [ ]  
 Apellido: [ ] Edad: [ ]  
 Nombre: [ ] Categoría de edad: [ ]  
 Sexo: [ ]

Localización  
 Institución: [ ] Tipo de localización: [ ]  
 Fecha de ingreso: [ ] Servicio: [ ]  
 Localización: [ ] Origen infección: [ ]

Muestra  
 Fecha de muestra: [ ] Número de muestra: [ ]  
 Tipo de muestra: [ ] Número de aislamiento: [ ]

Microbiología  
 Microorganismo: [ ]  
 BLEE: [ ]  
 Carbapenemase: [ ]  
 Resistencia inducible a la: [ ]  
 Antibiótico panel: Todos los antibióticos

Antibiotic panel:  Disco  CIM  Ettest

AMK	AMX	AMP	CTX
FOX	CAZ	CRO	CP
CLI	ERY	FUS	GEN
QEH	PM	LXX	LNZ
MEM	MET	MFX	NAL
NET	NOR	OFX	OXA
PEN	PP	TZP	GDA
RF	STR	TEC	TCY
TOB	SXT	VAN	DOR
AMB	ANI	MF	CAS
FCT	FLU	VOR	ITR
POS	ISV	AMB	ANI
MF	CAS	FCT	FLU
VOR	ITR	POS	ISV

Otro  
 Método de identificación: [ ]  
 Versión del software: [ ]  
 Gen amplificado para ID: [ ]  
 Método de sensibilidad: [ ]  
 Comentario: [ ]

Campos específicos para bacteriología

Como ejemplo de sensibilidad: al colocar el valor de la CIM o el diámetro del halo el programa realiza la interpretación:  
 S: sensible  
 I: intermedio  
 R: resistente  
 ?: No posee punto de corte  
 NS: no sensible

Al completar el campo Microorganismo se seleccionará el panel de antimicrobianos específico para ese microorganismo

Manual del Usuario

Los campos incluidos en el apartado Otro son específicos para micología

## Manual del Usuario WHONET

### Configuración e integración de protocolos

“Protocolo para el fortalecimiento de la vigilancia de la RAM basada en aislamientos en las Américas” y “Protocolo de implementación temprana para la inclusión de *Candida* spp. al GLASS”


Programa WHONET Versión 2019

#### Tabla de Contenidos

- Paso 1. Descarga del programa WHONET versión 2019
- Paso 2. Incorporación de la configuración del Laboratorio de la Organización Panamericana de la Salud (OPS) al WHONET
- Paso 3. Creación del *Laboratorio de su Hospital* adoptando la configuración del Laboratorio de la OPS
- Paso 4. Personalizando el laboratorio de su hospital
- Anexo 1. Variables e integración de ambos protocolos


WHONET  
 Variables e integración de ambos protocolos

# Q11: How would you estimate the investment needed to enable data collection and reporting to the PAHO following the new protocol?



- What kind of support is crucial for the successful implementation of the protocol?

## Q12: Regarding the participation (or plan to participate) in GLASS



- The Americas will be well represented on the map!
  - Very important to make our AMR situation known to the world
  - Keep the momentum/awareness & attention also of global funders!

# Transition period from aggregated to isolate level data 2019-21



## Suggested approach:

- All Latin American countries are requested to continue to share their 2018 & 2019 data via the Excel datasheet (memo)
- Caribbean countries will be requested to provide isolate level data (memo)
- Pilot countries, and Caribbean countries that are able will start sharing isolate level data using the standardized WHONET configuration (or same standard/cvs file)
  - Test phase followed by data submission of 2018/2019
  - Test datafiles will be used to create PLISA upload of data at regional level
- Define evaluation points/milestones February, June and October 2020, February 2021. Measure progress related to above steps and # countries able to provide (test) data (Flag challenges/blockers in time and act on them)

# Next steps for implementation



- Incorporate agreed changes for the **finalization of the protocol** – Dec 2019 (Eng/Spanish version)
  - Interactive session to discuss main points & final session on Day 3 to reach consensus on next steps
  - Opportunity to provide comments/suggestions **by email until Nov 10**
- Share **WHONET configuration and manual** available for early implementation – Oct 2019 (Eng/Spanish)
  - PAHO will work with WHONET (John Stelling) to finetune configuration and create WHONET PAHO specific export function
  - Provide **WebEx sessions** to provide guidance/explanation for the WHONET configuration – November 2019 (Eng – Uzo /Spanish - Agustina)
- **Share WHONET (test) data files** with PAHO – 2018/2019 data
- Provide individual country support
- Integration of AMR surveillance into **PLISA** – 2019/2020
- Follow the progress of implementation and evaluation points

PAHO/WHO



# OTRAS RECOMENDACIONES

# Programa de Control de la Calidad



- El Programa ha de ser mantenido y ampliado hasta cubrir todos los países que participan en la vigilancia de RAM
- Los países interesados en integrarse en el Programa han de comunicarse con el Programa Regional de RAM en la OPS
- Los paneles de control de calidad para Venezuela serán enviadas a través de Colombia (INS)



# MALDITOF y nuevas tecnologías



- WGS: trabajar en la integración de las diferentes áreas a nivel de los países
- MALDITOF: analizar el desarrollo de una red regional para bacteriología y micología

# Microorganismos productores de carbapenemas



- Desarrollar un plan de trabajo multidisciplinario para el fortalecimiento de la capacidad de los países en la contención de patógenos multirresistentes, en línea con las recomendaciones globales, regionales y nacionales.
- Organizar un grupo de trabajo para desarrollar un artículo usando los datos de RELAVRA, con un grupo de trabajo que coordine el proceso [propuesta]
- Iniciar el proceso de revisión / actualización del consenso MDR , XDR, PDR [nuevos patógenos?]

# Interaccion con otras redes



- Mantener y mejorar el intercambio de experiencias con redes de otras regiones (Europa) e iniciativas mundiales.
- A nivel regional:
  - Aquellas redes formadas por LNR - continuar con el intercambio de informacion y experiencias (WebEx, reuniones tecnicas, Proyecto de vigilancia RAM en hemocultivos, compartir uso de tecnologias o plataformas de informacion)
  - Aquellas redes formadas por otras instituciones: desde OPS, diseminacion de oportunidades de colaboracion e interaccion regionales con RILAA

Hacia la mejora de la completitud y la calidad de los datos en GLASS

## Otras propuestas



- OPS, en colaboración con los países, desarrollara proyectos y estrategias para fortalecer la participación plena de los LNR del Caribe de habla inglesa
  - Nombre para la Red?
- Asegurar y fortalecer la participación de los LNR en la evaluación del riesgo de resistencias emergentes en el marco del RSI – a nivel nacional

PAHO/WHO

# THANK YOU-GRACIAS-OBRIGADO

